Gardasil
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Silgard | — | 2006-09-19 | europa.eu ↗ |
Trials 85 · started per year
Also used as a comparator or background therapy in 35 trials
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 129 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gardasil | “The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical...” NCT00092521 ↗82“Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal...” NCT00325130 ↗ “Quadrivalent HPV vaccine (Gardasil) was given to the participants and serum anti-HPV antibody levels were measured at baseline (before first dose), 7 and 24months after the...” PMID 27406936 ↗ Jul 2016 “Gardasil® (Merck Canada Inc), the Quadravalent Human papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, was selected for this study for its efficacy and safety data in...” NCT02624349 ↗ “This phase IIIb trial compares a single dose of the Cervarix vaccine in girls to 3 doses of the Gardasil vaccine in young women for the prevention of human papillomavirus (HPV)...” NCT03728881 ↗ “The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women.” NCT01034358 ↗ “Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.” NCT00733122 ↗ “0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.” NCT00941889 ↗ “Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.” NCT00667563 ↗ “The purpose of the study is to understand if children with liver and kidney transplants develop the antibodies from the Gardasil vaccine.” NCT01101750 ↗ “A Randomized, Parallel Design Study to Compare the Safety and Effectiveness of Gardasil When Delivered Per Standard Practice” NCT02363660 ↗ “In a multi-centre cluster randomized trial of two vs three doses of quadrivalent HPV vaccination (Gardasil™) in India” PMID 29551226 ↗ Mar 2018 “A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)” NCT00090220 ↗ “In females over 25 years old, there was little to no difference between Cervarix and Gardasil compared with control” PMID 41276263 ↗ Nov 2025 “Gardasil® vaccine, when administered to girls 11-13 years of age according to 1 of 3 alternative 3-dose schedules” NCT00524745 ↗ “Food and Drug Administration (FDA)-approved quadrivalent HPV vaccine, Gardasil, at preventing anal HPV infection” NCT01461096 ↗ “V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years” NCT00092482 ↗ “Gardasil® 0.5 mL administered intramuscularly in the deltoid or anterolateral area of the thigh” NCT05435209 ↗ “Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)” NCT00505063 ↗ “Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.” NCT01424644 ↗ “Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.” NCT01209325 ↗ “quadrivalent HPV (types 6/11/16/18) L1 virus-like particle vaccine (GARDASIL)” PMID 23331518 ↗ Mar 2013 “Immunogenicity and Safety of One Dose of Cecolin and One Dose of Gardasil” NCT06345885 ↗ “Gardasil-controlled (quadrivalent HPV vaccine GARDASIL®)” NCT05694728 ↗ “GARDASIL™ (quadrivalent human papillomavirus” NCT00337428 ↗ “3-dose schedule of Gardasil®” NCT06281119 ↗ |
| Known as | 4-Valent HPV Vaccine | “Gardasil (4-Valent HPV Vaccine)” NCT00543543 ↗ |
| Known as | 4vHPV | “There are no randomized studies comparing the long-term effectiveness of a 2-dose schedule (administered at 0 and 6 months) of quadrivalent human papillomavirus vaccine (4vHPV)...” PMID 40627355 ↗ Jul 20251“Gardasil® (4vHPV) is a recombinant protein particulate (VLP) vaccine.” NCT04590521 ↗ |
| Known as | 9vHPV | “nonavalent HPV (9vHPV) vaccine” NCT07431502 ↗ |
| Known as | 9vHPV vaccine | “The candidate E. coli-produced 9vHPV vaccine has been preliminarily proven to be well tolerated and immunogenic, which encourages further studies in large cohorts with a wider...” PMID 37283969 ↗ Mar 2023 |
| Known as | GARDASIL (HPV) | “GARDASIL® (HPV)” NCT02199691 ↗ |
| Known as | Gardasil Quadrivalent HPV Types 6, 11, 16, 18 | “Participants received three doses of quadrivalent HPV vaccine (Gardasil Quadrivalent HPV Types 6, 11, 16, 18) and were followed up between 2007 and 2016 (60months post-vaccination).” PMID 31402238 ↗ Aug 2019 |
| Known as | Gardasil, HPV vaccine | “Gardasil, HPV vaccine” NCT00829608 ↗ |
| Known as | Gardasil-4 | “Gardasil-4 single dose” NCT07256912 ↗ |
| Known as | HPV (Human Papillomavirus) Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00501137 ↗ |
| Known as | HPV Vaccine | “HPV Vaccine (Gardasil)” NCT01096134 ↗ |
| Known as | HPV4 | “Participants received three intramuscular doses of either quadrivalent HPV vaccine (HPV4; enrolments on or before March 1, 2016) or nonavalent HPV vaccine (HPV9; enrolments...” PMID 34767765 ↗ Nov 2021 |
| Known as | Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00949572 ↗ |
| Known as | Human papillomavirus quadrivalent vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00677677 ↗ |
| Known as | Human Papillomavirus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01928225 ↗ |
| Known as | qHPV | “The Base study vaccination period (V501-019) encompassed Day 1 through Month 7, during which time participants received randomly assigned, blinded Gardasil™ (V501, qHPV...” NCT00090220 ↗1“The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and...” PMID 35997582 ↗ Aug 2022 |
| Known as | qHPV vaccine | “qHPV vaccine” NCT01928225 ↗ |
| Known as | Quadravalent Human papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | “Gardasil® (Merck Canada Inc), the Quadravalent Human papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, was selected for this study for its efficacy and safety data in...” NCT02624349 ↗ |
| Known as | quadrivalent HPV vaccine | “Participants received three intramuscular doses of either quadrivalent HPV vaccine (HPV4; enrolments on or before March 1, 2016) or nonavalent HPV vaccine (HPV9; enrolments...” PMID 34767765 ↗ Nov 20218“Quadrivalent HPV vaccine (Gardasil) was given to the participants and serum anti-HPV antibody levels were measured at baseline (before first dose), 7 and 24months after the...” PMID 27406936 ↗ Jul 2016 “Patients were immunized with three doses of quadrivalent HPV vaccine containing viral types 6, 11, 16 and 18.” PMID 23837399 ↗ Jul 2013 “Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.” NCT00380367 ↗ |
| Known as | Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ) | “Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)” NCT01512784 ↗ |
| Known as | Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine | “0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.” NCT00520598 ↗7“Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.” NCT00551187 ↗ “Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.” NCT01424644 ↗ |
| Known as | Quadrivalent Human Papillomavirus Recombinant vaccine | “Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.” NCT00667563 ↗ |
| Known as | Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) | “This phase I clinical study was designed to evaluate the safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter called HPV...” NCT03813940 ↗ |
| Known as | SILGARD | “BACKGROUND: GARDASIL/SILGARD is a quadrivalent human papillomavirus (HPV) vaccine with activity against HPV 6/11/16/18.” PMID 19952980 ↗ Apr 20102“Quadrivalent human papilloma virus (HPV) [types 6, 11, 16, 18] recombinant vaccine (Gardasil®; Silgard®)” PMID 21142263 ↗ Dec 2010 |
| Known as | Tetravalent Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01717118 ↗ |
| Known as | V501 | “The Base study vaccination period (V501-019) encompassed Day 1 through Month 7, during which time participants received randomly assigned, blinded Gardasil™ (V501, qHPV...” NCT00090220 ↗12“Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal...” NCT00325130 ↗ “V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine” NCT00517309 ↗ “Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)” NCT00337428 ↗ |
| Modality | Vaccine | “quadrivalent HPV vaccine” PMID 34780705 ↗ Nov 2021 |
| Route | Intramuscular | “0.5 mL intramuscular injection in the deltoid muscle” NCT00090285 ↗ |